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Following our recent observation that alterations of the Natural Killer (NK) cell compartment in the presence of BCR-
ABLinduced  myeloproliferation  fail  to  revert  under  targeted  therapy,  we  discuss  by  what  mechanisms  oncogenic 
molecular pathways and their pharmacological inhibition may interfere with immune functions. Rational combinations 
of molecularly targeted and immunological strategies may provide a means for more e ective cancer targeting.
Natural killer (NK) cells are attractive effec-
tor cells of therapeutic antitumor immune 
activation, since they have potent cytolytic 
effector function and can amplify adaptive 
immune responses by interacting with vari-
ous immune effector and antigenpresent-
ing cells. Functional and immunogenetic 
studies  suggest  that  autologous  NK  cells 
contribute to immune surveillance of both 
leukemias and solid tumors.1,2 Conversely, 
suppression  of  NK-cell  mediated  effector 
function can contribute to tumor escape 
from immune control.
In  our  recent  article  published  in 
Leukemia,3 we have reported that the NK 
cell  compartment  is  impaired  in  chronic 
myelogenous  leukemia  (CML).  We  have 
identiﬁed  profound  quantitative  and 
functional  NK  cell  defects  in  patients 
with newly diagnosed CML. These aber-
rations were mimicked in a mouse model 
of  CML-like  myeloproliferation  induced 
by BCR-ABL expression in hematopoietic 
stem cells. Thus, the disease-driving aber-
rant tyrosine kinase activity appears to be 
involved in NK cell dysfunction. Since NK 
cells in CML are not part of the malignant 
clone,  we  concluded  that  the  malignant 
environment  is  likely  responsible  for  the 
observed alterations. 
Remarkably, targeted therapy with ima-
tinib failed to restore NK cell function even 
in patients achieving molecular remissions. 
This raises the question to what extent and 
in what way the drug may interfere with the 
immune system.
Imatinib is the most prominent example 
for  a  new  generation  of  anticancer  drugs. 
Progress  in  understanding  the  molecular 
architecture and functional circuits of cancer 
cells has led to clinical evaluation of agents 
that selectively target relevant signaling path-
ways. By inhibiting the aberrant BCR-ABL 
tyrosine kinase, imatinib has revolutionized 
the  treatment  of  CML.4  Development  of 
molecularly  targeted  drugs  has  focused  on 
their  direct  effects  on  disease-driving  and 
disease-related pathways in tumor cells. More 
recently, there is an increasing awareness of 
the signiﬁcance of the surrounding nonmalig-
nant stroma for tumor development and sus-
tenance. Stroma besides ﬁbroblasts and cells 
of vascular structures includes various com-
ponents of the immune system, and evidence 
is now accumulating that targeted drugs can 
modulate immune functions in a complex 
manner. Besides imatinib and the follow-up 
compounds dasatinib and nilotinib, various 
inhibitors  of  receptor-induced  and  intracel-
lular pathways (e.g., AKT/mTOR) as well as 
drugs  that  target  epigenetic  transcriptional 
control were found to exert differential effects 
on  individual  immune  cell  subpopulations 
and antigen-speciﬁc effector cells.
These  observations  are  not  unex-
pected,  since  molecular  targeting  is  not 
cancerspeciﬁc. Pathways involved in onco-
genic  receptor  and  intracellular  tyrosine 
kinase signaling are also important for the 
functionality, proliferation and survival of 
immune  effector  cells.5  Moreover,  drugs 
generally interact with more than one path-
way.  E.g.  imatinib  is  also  active  against 
c-KIT and platelet-derived growth factor 
receptor (PDGFR), and the newer tyrosine 
kinase inhibitors have even broader activ-
ity.  Therefore,  systemic  treatment  with 
molecularly targeted agents acts not only 
on the tumor cells, but also affects various 
other cell types (Fig. 1). Imatinib again, 
by its interaction with the c-KIT receptor, 
was shown to interfere with the licensing 
of c-KITexpressing DCs to activate resting 
NK cells in vivo.6
Recent evidence further illustrates that 
therapeutic  inhibition  of  oncogenic  path-
ways can affect tumor host interactions by 
altering the immunogenicity and immuno-
modulatory function of targeted tumor cells. 
The efﬁcacy of imatinib in a mouse model of 
gastrointestinal stroma tumors (GIST) criti-
cally depended on CD8+ T cells, suggesting 
that the drug in this model acts at least in part 
by amplifying a preexisting T cell response.7 
Inhibition  of  oncogenic  Kit  expression  in 
GIST cells resulted in reduced expression 
of the immunomodulatory molecule IDO, 
subsequent activation of intratumoral CD8+ 
T cells and apoptosis of regulatory T cells
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imatinib was shown to reduce immuno-
genicity by interfering with the BCR-ABL-
induced upregulation of immunogenic
antigens and thereby to impair antigen-
specific T cell responses.
8
What is the relevance of interference
by molecularly targeted drugs with the
tumor-interacting immune functions?
Despite the efficacy of tyrosine kinase
inhibitors to induce and maintain remis-
sions, CML patients are rarely cured by
these drugs. BCR-ABL expressing leuke-
mic stem cells persist even in the sustained
absence of detectable molecular residual
disease
9 and may reinitiate leukemic
growth. By contrast, immunological
graft-vs.-leukemia reactions in the context
of allogeneic hematopoietic stem cell
transplantation can eradicate the disease.
Moreover, in mouse models, an intact
immune system was required for sustained
tumor regression upon inactivation of
disease-driving oncogenes.
10 Thus, mole-
cularly targeted drugs should be selected
not only for their direct, on-target anti-
tumor effects, but also for their capacity
to interfere with immune escape, activate
various components within the immune
microenvironment and initiate and main-
tain potent and sustained anticancer
immune responses. This requires detailed
studies of the effects of drug treatment
on immune effector cells and dissection
of the mechanisms by which molecular
pathways affect tumor-host immune
responses. Moreover, the potential of
combined molecular and immune target-
ing will need to be explored. Preferably,
the effects of combination therapies
should be studied within the tumor micro-
environment where the most relevant
tumor-immune interactions are likely
to take place. The mouse model that
we used in our study closely mimics
BCR-ABL-driven myeloproliferation and
proved suitable for studying the role of
aberrant tyrosine kinase expression in NK
cell dysfunction. However, its application
to the investigation of tyrosine kinase
inhibition on the immune system is
limited by differences in clonal origins
and target expression between patients and
mice. The generation of adequate models
for studying these interactions remains a
challenge.
We conclude that the effects of mole-
cularly targeted agents on the immune
system deserve close attention. Strategies
should be explored that target disease-
driving pathways in tumor cells while
at the same time suppressing immune
escape mechanisms, inducing tumor-
specific immune activation inside tumors
and thereby providing long-term immune
control over residual cancer cells.
Figure1. Role of molecular pathway inhibition in tumor host immune interactions. Tumor-host immune interactions within the microenvironment are
critical for tumor development and sustained tumor growth. Complex crosstalks between various immune effector cells, antigen-presenting cells and
tumor cells yield an integrated outcome toward either antitumor immune activation or tolerance. Oncogenic alterations within molecular pathways in
tumor cells as well as therapeutic inhibition of these pathways in tumor cells, along with both on- and off-target effects of targeted drugs in immune
cells, interfere with this network, affect functional tumor immune responses, and may be exploited for more effective therapies.
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